December 22nd 2025
Abbott's Volt PFA System gains FDA approval, offering a new minimally invasive treatment for atrial fibrillation, enhancing patient care options.
Oral Anticoagulants Top Antiplatelet Drugs for Stroke Prevention in A-Fib
July 18th 2007ROCHESTER, Minn. -- Patients with nonvalvular atrial fibrillation have about a 33% lower risk of stroke and major vascular events when treated with oral anticoagulants rather than antiplatelet therapy, findings from a systematic review of clinical trials suggest.
Sildenafil Boosts the Heart's Performance, Too
July 12th 2007EDMONTON, Alberta -- Phosphodiesterase type 5 (PDE5) drugs, such as sildenafil (Viagra), may improve right ventricular contractility in hearts with right ventricular hypertrophy, an unexpected benefit that looks promising for treatment of right ventricular heart failure.
Preventing pulmonary embolism with vena caval filters
July 1st 2007* Vena caval interruption has been used in the treatment of deep venous thrombosis (DVT) to prevent PE since the early 1970s. Filter placement has been increasing in the past decade. We estimate that filters are placed in more than 0.2% of all Medicare recipients annually.
Heart Failure: Part 1, Diagnosis and Staging
July 1st 2007Heart failure is prevalent in both primary care and cardiology practices. It develops in about 1 in 5 persons during their lifetime and in about 1 in 8 of those who have not sustained a myocardial infarction (MI). Heart failure is also the leading cause of hospitalization in the elderly.
Ventricular Tachycardia in Acute Myocardial Infarction
July 1st 2007A 67-year-old woman arrived via ambulance in ventricular tachycardia. She had been experiencing crushing substernal chest pain and shortness of breath that had worsened over the past several hours. She received oxygen (by mask) and lidocaine (100 mg intravenously) en route to the emergency department (ED), but there was no change in the rhythm.
ADA: Avandia Critic Meets Skeptical Diabetologists
June 26th 2007CHICAGO -- When the spotlight here focused on rosiglitazone (Avandia) and its harshest critic, Steven E. Nissen, M.D., of the Cleveland Clinic, the cardiologist offered a mild apology to a room full of diabetologists for complicating their lives.